We recently demonstrated the medical plausibility of ciclopirox (CPX) for the treatment of CEP, acting as a pharmacological chaperone targeting uroporphyrinogen III synthase [3]. This evidence concerns the gene UROS and Congenital erythropoietic porphyria.